Are you on LinkedIn? If so, we'd love to connect with you! Visit our profile at https://ca.linkedin.com/company/canadian-cancer-survivor-network and be sure to follow us!
If you are interested in being part of the Canadian Cancer Survivor Network’s All-Party Cancer Caucuses at the Ontario legislature in Toronto or the Alberta legislature in Edmonton, there is...
The Canadian Cancer Action Network (CCAN), in collaboration with CADTH, are pleased to announce that they are launching an enhanced Cancer Drug Information Pipeline for Patient Groups by transitioning it to...
Have you been diagnosed with head and neck cancer and want to get more involved in the cancer community? CCSN has several advisory councils, and we’re now starting a new...
The Canadian Cancer Action Network, in partnership with Carers Canada and the Canadian Home Care Association, is pleased to publically launch the 2017 report, Advancing Collective Priorities: A Canadian Carer...
New criteria for the following products have been added to the Newfoundland and Labrador Prescription Drug Program (NLPDP) Benefit List effective June 1, 2017. Special Authorization New Addition The following...
A research ethics board (REB) is a body of researchers, community members and others that is established to review the ethical acceptability of research involving humans. Working within a defined...
EDMONTON, AB. - July 19th, 2017 – The provincial/territorial Premiers met today at the Council of the Federation in Edmonton, Alberta. Health was on the agenda. Patient groups, patients, caregivers...
COBIMETINIB: in association with vemurafenib, for first-line or second-line treatment following a failure with cytotoxic chemotherapy or with immunotherapy targeting the PD-1 or the CTLA-4, of an unresectable or metastatic...
EDMONTON, AB. - July 18th, 2017 – The provincial/ territorial Premiers are meeting today and tomorrow at the Council of the Federation meeting in Edmonton, Alberta. Patient groups, patients, caregivers...